ImpediMed Limited announced the details of the third contract extension related to the use of the SOZO Digital Health Platform in a clinical trial being conducted for AstraZeneca. The Phase IIb trial is using the SOZO to track patient fluid volume in a pharmaceutical study focused on chronic kidney disease. The trial has been extended from 21 months to 29 months, with 210 SOZO devices being utilised in the extension.

In total, the contracts will generate over $6.7 million in revenue across the trials. The Company recognised approximately $5.7 million in revenue to date (through 30 September 2022) under these contracts. The remaining $1.0 million of the revenue will be recognised throughout the remainder of the 2023 financial year.

The Company previously announced AstraZeneca is using SOZO to track patient fluid volume in two separate clinical trials. A combined 434 SOZO devices have been leased across over 28 countries over the course of both trials. The first trial was focused on heart failure and chronic kidney disease and the second only on chronic kidney disease.

The use of SOZO in that trial is now complete. The current AstraZeneca trial that has been extended is using SOZO to monitor body fluid volumes as they evaluate the efficacy, safety and tolerability of a combination of two AstraZeneca drugs in heart failure patients with chronic kidney disease. This Phase IIb trial began in November 2020 and the use of SOZO within the trial is now scheduled to be completed in April 2023.

The trial is being run by a contract research organisation on behalf of AstraZeneca. Under the terms of the agreement, and in alignment with the Company's SaaS business model, each device will have a monthly license fee for the duration of the trial. ImpediMed will retain ownership of the devices at the conclusion of the trials.